 |
| Attached files |
| File | Filename |
|---|
| EXCEL - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | Financial_Report.xls |
| 10-K - FORM 10-K - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_10k.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R8.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R5.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R4.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R9.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R1.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R7.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R12.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R13.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R15.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R20.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R11.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R19.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R16.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R18.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R17.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R21.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R22.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R14.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R10.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R6.htm |
| EX-31.1 - EXHIBIT 31.1 - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_ex31-1.htm |
| EX-32 - EXHIBIT 32 - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_ex32.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R2.htm |
| EX-31.2 - EXHIBIT 31.2 - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_ex31-2.htm |
v2.4.0.6
|
Consolidated Balance Sheets [Parenthetical] (USD $)
|
Dec. 31, 2011
|
Dec. 31, 2010
|
| Related party accounts payable |
$ 452,000 |
$ 250,000 |
| Related party accrued expense |
$ 460,000 |
$ 360,000 |
| Common stock, par value (in dollars per share) |
$ 0.001 |
$ 0.001 |
| Common stock, shares authorised |
147,397,390 |
147,397,390 |
| Common stock, shares issued |
21,370,725 |
21,149,675 |
| Common stock, shares outstanding |
21,370,725 |
21,149,675 |
| X |
- Definition
Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
| Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
num:perShareItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
| Name: |
us-gaap_CommonStockSharesAuthorized |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
| Name: |
us-gaap_CommonStockSharesIssued |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
| X |
- Definition
Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
+ Details
| Name: |
us-gaap_CommonStockSharesOutstanding |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
instant |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by ONCOVISTA INNOVATIVE THERAPIES, INC and has no official or unofficial affiliation with ONCOVISTA INNOVATIVE THERAPIES, INC
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
